Synonyms: BAY 1213790 | BAY-1213790 | BAY1213790
Compound class:
Antibody
Comment: Osocimab (BAY 1213790) is a fully humanized monoclonal antibody that targets activated Factor XI [1]. It is being investigated for clinical prevention of thrombosis [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
No information available. |
Summary of Clinical Use |
Osocimab has been advanced to clinical trial for prevention of thrombosis in select patient groups [2]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03276143 | FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty | Phase 2 Interventional | Bayer | Compared with enoxaparin, osocimab met criteria for superiority in preventing post-operative venous thromboembolism. | 2 |
NCT04523220 | Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis | Phase 2 Interventional | Bayer |